0000000000895262

AUTHOR

Antonio Vitale

showing 29 related works from this author

Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease

2019

Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 7…

0301 basic medicineAdult onset Still diseasemedicine.medical_specialtyArthritisStill DiseaseAdult onset Still disease; Anakinra; Drug retention rate; Innovative biotechnologies; Interleukin 1-beta; Personalized medicine; Systemic juvenile idiopathic arthritis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticaanakinra interleukin 1-beta innovative biotechnologies drug retention rate systemic juvenile idiopathic arthritis adult onset Still disease personalized medicineSystemic juvenile idiopathic arthritisInternal medicinemedicinePharmacology (medical)Adverse effectOriginal ResearchPharmacologyAnakinrabusiness.industryHazard ratiolcsh:RM1-950Innovative biotechnologiesmedicine.diseaseDrug retention ratePersonalized medicineConfidence intervalAdult onset Still disease Anakinra Drug retention rate Innovative biotechnologies Interleukin 1-beta Personalized medicine Systemic juvenile idiopathic arthritisDiscontinuation030104 developmental biologylcsh:Therapeutics. PharmacologyAnakinraInnovative biotechnologie030220 oncology & carcinogenesisCohortInterleukin 1-betabusinessmedicine.drug
researchProduct

The ATLAS Simulation Infrastructure

2010

52 páginas, 10 figuras, 18 tablas.-- This article is distributed under the terms of the Creative Commons Attribution Noncommercial License.-- et al. (The ATLAS Collaboration).

LibraryPhysics - Instrumentation and DetectorsPhysics and Astronomy (miscellaneous)Physics::Instrumentation and Detectorscomputer.software_genre01 natural sciencesHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Statistical physicsDetectors and Experimental TechniquesSimulaciónphysics.ins-detDetectors de radiació/dk/atira/pure/subjectarea/asjc/2200/2201PhysicsLarge Hadron ColliderAtlas (topology)4. EducationAcceleradors de partículesATLAS experimentDetectorSettore FIS/01 - Fisica SperimentaleInstrumentation and Detectors (physics.ins-det)ATLASGridSimulation softwareTile CalorimeterPhysical SciencesMontecarlo simulationLHCReal-time computingFOS: Physical sciencesATLAS experimentddc:500.2530High-Energy Physics0103 physical sciencesFysikddc:530[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]High Energy PhysicsMonte-Carlo010306 general physicsPartonEngineering (miscellaneous)Ciencias ExactasGEANT4EventATLAS detector010308 nuclear & particles physicsFísicaATLAS experiment; Montecarlo simulation; LHCGrid computingInterfacingHigh Energy Physics::Experiment/dk/atira/pure/subjectarea/asjc/3100/3101computer
researchProduct

Search for an excess of events with an identical flavour lepton pair and significant missing transverse momentum in root s=7 TeV proton-proton collis…

2011

Results are presented of a search for supersymmetric particles decaying into final states with significant missing transverse momentum and exactly two identical flavour leptons (e or mu) of opposite charge in sqrt{s}=7 TeV collisions at the Large Hadron Collider. This channel is particularly sensitive to supersymmetric particle cascade decays producing flavour correlated lepton pairs. Flavour uncorrelated backgrounds are subtracted using a sample of opposite flavour lepton pair events. Observation of an excess beyond Standard Model expectations following this subtraction procedure would offer one of the best routes to measuring the masses of supersymmetric particles. In a data sample corres…

Particle physicsPhysics and Astronomy (miscellaneous)Physics beyond the Standard ModelFlavourSupergauge TransformationsFOS: Physical sciencesddc:500.2Parameter space01 natural sciences530Settore FIS/04 - Fisica Nucleare e SubnucleareHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)Pionsparticle: cascade decay ; sparticle: search for ; electron: pair production ; muon: pair production ; p p: inelastic scattering ; transverse momentum: missing-energy ; supersymmetry: parameter space ; CERN LHC Coll ; new physics ; ATLAS ; dilepton: mass spectrum ; experimental results ; 7000 GeV-cmsPions0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]FysikHigh Energy Physics010306 general physicsEngineering (miscellaneous)PhysicsLarge Hadron ColliderScience & TechnologyATLAS detector010308 nuclear & particles physicsSettore FIS/01 - Fisica SperimentaleHigh Energy Physics::PhenomenologyATLASGeneratorsCascadeTransverse momentumPhysical SciencesExperimental High Energy PhysicsComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFísica nuclearHigh Energy Physics::ExperimentLHCParticle Physics - ExperimentLeptonModel
researchProduct

Development and implementation of the AIDA international registry for patients with Still's disease

2022

ObjectiveAim of this paper is to present the design, construction, and modalities of dissemination of the AutoInflammatory Disease Alliance (AIDA) International Registry for patients with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD), which are the pediatric and adult forms of the same autoinflammatory disorder.MethodsThis Registry is a clinical, physician-driven, population- and electronic-based instrument implemented for the retrospective and prospective collection of real-world data. The collection of data is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain evidence drawn from routine patients' management. The co…

RegistrySettore MED/16 - REUMATOLOGIAresearchtreatmentprecision medicinerare diseasesGeneral Medicinepersonalized medicineautoinflammatory diseasesSettore MED/38 - Pediatria Generale E Specialisticaautoinflammatory diseases personalized medicine precision medicine rare diseases research treatmentStill's diseaseautoinflammatory diseases; personalized medicine; precision medicine; rare diseases; research; treatmentHuman medicine
researchProduct

Adult-onset Still's disease with elderly onset: results from a multicentre study

2021

Objective In this study, we aimed to describe the clinical characteristics, life-threatening complications occurrence, and mortality of adult-onset Still's disease (AOSD) patients with elderly onset. Methods A multicentre retrospective study of prospectively followed-up AOSD patients included in Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort was performed. Results Out of 221 assessed patients, 37 (16.7%) had an onset of the disease aged over 60 years. When compared with younger patients, these were characterised by a higher prevalence of pericarditis (p=0.008), comorbidities (p < 0.0001), and mortality (p=0.023). Age predicted the presence of serositis …

Lung DiseasesAdult-OnsetAdultcomorbiditieImmunologyadult-onset Still's diseasecomorbiditiesLung Diseaseserositisadult-onset Still's disease; aging; serositis; parenchymal lung disease; comorbidities; Adult; Aged; Humans; Middle Aged; Retrospective Studies; Lung Diseases; Macrophage Activation Syndrome; Serositis; Still's Disease Adult-OnsetRheumatologyRetrospective StudieImmunology and AllergyHumansRetrospective StudiesAgedcomorbidities.SerositiMacrophage Activation SyndromeagingMiddle AgedStill's Diseaseadult-onset Still's disease; aging; serositis; parenchymal lung disease; comorbiditiesStill's Disease Adult-Onsetparenchymal lung diseaseHuman
researchProduct

Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome

2022

ObjectiveThe aim of this paper is to present the AutoInflammatory Disease Alliance (AIDA) international Registry dedicated to Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome, describing its design, construction, and modalities of dissemination.MethodsThis Registry is a clinical, physician-driven, population- and electronic-based instrument designed for the retrospective and prospective collection of real-life data. Data gathering is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain real-world evidence for daily patients' management. The Registry may potentially communicate with other on-line tools dedicated to VEXAS syndrome, thu…

RegistryKeywords: autoinflammatory diseases; clinical management; precision medicine; rare diseases; research; treatment.Settore MED/16 - REUMATOLOGIAresearchtreatmentprecision medicinerare diseasesrare diseaseGeneral Medicineautoinflammatory diseasestreatment.Settore MED/38 - Pediatria Generale E Specialisticaautoinflammatory diseaseVEXAS syndromeclinical managementHuman medicineKeywords: autoinflammatory diseases
researchProduct

Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life exp…

2022

ObjectiveInterleukin (IL)-1 inhibitors are largely employed in patients with Still’s disease; in cases with refractory arthritis, IL-6 inhibitors have shown to be effective on articular inflammatory involvement. The aim of the present study is to assess any difference in the effectiveness of the IL-1β antagonist canakinumab prescribed as first-line biologic agent between the systemic and the chronic-articular Still’s disease.MethodsData were drawn from the retrospective phase of the AutoInflammatory Disease Alliance (AIDA) international registry dedicated to Still’s disease. Patients with Still’s disease classified according to internationally accepted criteria (Yamaguchi criteria and/or Fa…

AOSD; adult onset Still’s disease; autoinflammatory diseases; biological therapy; interleukin-1; sJIA; systemic juvenile idiopathic arthritisadult onset Still’s diseaseAOSD adult onset Still’s disease autoinflammatory diseases biological therapy interleukin-1 sJIA systemic juvenile idiopathic arthritisSettore MED/38 - Pediatria Generale E Specialisticasystemic juvenile idiopathic arthritisbiological therapyAOSDGeneral Medicineautoinflammatory diseasesinterleukin-1sJIAFrontiers in Medicine
researchProduct

Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease

2022

Abstract Objective To compare clinical features and treatments of patients with systemic JIA (sIJA) and adult-onset Still’s disease (AOSD). Methods The clinical charts of consecutive patients with sJIA by International League of Association of Rheumatology criteria or AOSD by Yamaguchi criteria were reviewed. Patients were seen at a large paediatric rheumatology referral centre or at 10 adult rheumatology academic centres. Data collected included clinical manifestations, inflammation biomarkers, systemic score, macrophage activation syndrome (MAS), parenchymal lung disease, disease course, disability, death and medications administered. Results A total of 166 patients (median age at diagnos…

AdultLung DiseasesBiological ProductsMacrophage Activation SyndromeArthritis JuvenileSystemic juvenile idiopathic arthritis; adult-onset Still’s diseaseRheumatologyAdrenal Cortex HormonesSystemic juvenile idiopathic arthritisAntirheumatic AgentsFerritinsPrevalenceSystemic juvenile idiopathic arthritiHumansadult-onset Still’s diseasePharmacology (medical)ChildStill's Disease Adult-OnsetBiomarkersAcute-Phase Proteins
researchProduct

Drift Time Measurement in the ATLAS Liquid Argon Electromagnetic Calorimeter using Cosmic Muons

2010

The ionization signals in the liquid argon of the ATLAS electromagnetic calorimeter are studied in detail using cosmic muons. In particular, the drift time of the ionization electrons is measured and used to assess the intrinsic uniformity of the calorimeter gaps and estimate its impact on the constant term of the energy resolution. The drift times of electrons in the cells of the second layer of the calorimeter are uniform at the level of 1.3% in the barrel and 2.8% in the endcaps. This leads to an estimated contribution to the constant term of (0.29-0.04+0.05)% in the barrel and (0.54-0.04+0.06)% in the endcaps. The same data are used to measure the drift velocity of ionization electrons …

Drift velocityPhysics - Instrumentation and DetectorsPhysics and Astronomy (miscellaneous)Physics::Instrumentation and DetectorsInstrumentationFOS: Physical sciencesddc:500.2ElectronAstrophysics::Cosmology and Extragalactic AstrophysicsElectromagnetic CalorimeterATLAS; Drift Time Measurement; Cosmic Muons5307. Clean energy01 natural sciencesPartícules (Física nuclear)High Energy Physics - Experiment010305 fluids & plasmasNuclear physicsHigh Energy Physics - Experiment (hep-ex)Atlas (anatomy)Ionization0103 physical sciencesmedicineFysikddc:530High Energy Physics[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]Cosmic MuonsDetectors and Experimental Techniques010306 general physicsEngineering (miscellaneous)Ciencias ExactasDetectors de radiacióPhysicsCalorimeter (particle physics)010308 nuclear & particles physicsAcceleradors de partículesResolution (electron density)Instrumentation and Detectors (physics.ins-det)ATLASliquid argonElectromagnetic calorimetermedicine.anatomical_structureExperimental High Energy PhysicsDrift Time MeasurementPhysical SciencesComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHigh Energy Physics::ExperimentLHC
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

Readiness of the ATLAS Tile Calorimeter for LHC collisions

2010

67 páginas.-- El PDF es la versión pre-print (arXiv:1007.5423v2).-- The ATLAS Collaboration.-- et al.

SystemPhysics - Instrumentation and DetectorsPhysics and Astronomy (miscellaneous)Physics::Instrumentation and DetectorsPerformance7. Clean energy01 natural sciences030218 nuclear medicine & medical imagingSettore FIS/04 - Fisica Nucleare e SubnucleareHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)0302 clinical medicine[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Detectors and Experimental TechniquesDetectors de radiaciócosmic rayPhysicsLarge Hadron ColliderDetectorSettore FIS/01 - Fisica SperimentaleAstrophysics::Instrumentation and Methods for AstrophysicsInstrumentation and Detectors (physics.ins-det)ATLASmedicine.anatomical_structureScintillatorsPhysical Sciencesmagnetic-fields; scintillators; electronics; performance; systemLHCCol·lisionadors d'hadronsPhotomultiplierFOS: Physical sciencesCosmic rayddc:500.2Noise (electronics)530LHC collisions; AtlasNuclear physics03 medical and health sciencesAtlas (anatomy)0103 physical sciencesCalibrationmedicinetile hadronic calorimeterFysikddc:530High Energy Physics[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]010306 general physicsEngineering (miscellaneous)Ciencias ExactasCalorimeter (particle physics)010308 nuclear & particles physicsFísicaMagnetic-FieldsHigh Energy Physics::ExperimentElectronics
researchProduct

Development and implementation of the AIDA international registry for patients with Schnitzler's syndrome.

2022

ObjectiveThe present paper describes the design, development, and implementation of the AutoInflammatory Disease Alliance (AIDA) International Registry specifically dedicated to patients with Schnitzler's syndrome.MethodsThis is a clinical physician-driven, population- and electronic-based registry implemented for the retrospective and prospective collection of real-life data from patients with Schnitzler's syndrome; the registry is based on the Research Electronic Data Capture (REDCap) tool, which is designed to collect standardized information for clinical research, and has been realized to change over time according to future scientific acquisitions and potentially communicate with other…

RegistrySettore MED/38 - Pediatria Generale E SpecialisticaSchnitzler syndromeSettore MED/16 - REUMATOLOGIAautoinflammatory diseasebiotherapiesbiotherapierare diseaseGeneral Medicineautoinflammatory disease; biotherapies; interleukin-1; international registry; personalized medicine; rare diseasepersonalized medicineinternational registryinterleukin-1Frontiers in medicine
researchProduct

The AutoInflammatory Diseases Alliance Registry of monogenic autoinflammatory diseases

2022

ObjectiveThe present manuscript aims to describe an international, electronic-based, user-friendly and interoperable patient registry for monogenic autoinflammatory diseases (mAIDs), developed in the contest of the Autoinflammatory Diseases Alliance (AIDA) Network.MethodsThis is an electronic platform, based on the Research Electronic Data Capture (REDCap) tool, used for real-world data collection of demographics, clinical, laboratory, instrumental and socioeconomic data of mAIDs patients. The instrument has flexibility, may change over time based on new scientific acquisitions, and communicate potentially with other similar registries; security, data quality and data governance are corner …

RegistrySettore MED/38 - Pediatria Generale E SpecialisticaSettore MED/16 - REUMATOLOGIAautoinflammatory diseaseprecision medicineAutoinflammatory diseasesrare diseasesHuman medicinepersonalized medicineGeneral Medicinerare diseases.autoinflammatory diseases; international registry; personalized medicine; precision medicine; rare diseasesinternational registry
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct

Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network

2020

Objective. To analyze the potential role of colchicine monotherapy in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) in terms of control of clinical and laboratory manifestations. Methods. Patients with TRAPS treated with colchicine monotherapy were retrospectively enrolled; demographic, clinical and therapeutic data were collected and statistically analysed after having clustered patients according to different times at disease onset, penetrance of mutations, dosage of colchicine, and different disease manifestations. Results. 24 patients (14 males; 15 with pediatric disease onset) treated with colchicine monotherapy were enrolled. Colchicine resulted in …

Male0301 basic medicineEye DiseasesTRAPSColchicineAIDA NetworkGene mutationGastroenterologyReceptors Tumor Necrosis Factorchemistry.chemical_compoundSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineReceptorsPathologyRB1-214ColchicineAge of OnsetYoung adultChildAmyloidosisAmyloidosisSyndromeMiddle AgedColchicine tumor necrosis factor TRAPSInflamacióPenetrancePhenotypeChild PreschoolFemaleJoint DiseasesResearch ArticleAdultRiskmedicine.medical_specialtyAdolescentFeverArticle SubjectImmunologyAdolescent; Adult; Age of Onset; Amyloidosis; Child; Child Preschool; Colchicine; Exanthema; Eye Diseases; Female; Fever; Humans; Joint Diseases; Male; Middle Aged; Mutation; Myalgia; Phenotype; Receptors Tumor Necrosis Factor; Retrospective Studies; Risk; Syndrome; Young AdultLower riskYoung Adult03 medical and health sciencesInternal medicinemedicineHumansPreschoolRetrospective StudiesInflammation030203 arthritis & rheumatologybusiness.industryTRAPSRetrospective cohort studyMyalgiaCell BiologyExanthemamedicine.disease030104 developmental biologychemistryMutationAge of onsetColchicineTumor Necrosis FactorbusinessMediators of Inflammation
researchProduct

Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A S…

2020

This study explores demographic, clinical, and therapeutic features of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a cohort of 80 patients recruited from 19 Italian referral Centers. Patients’ data were collected retrospectively and then analyzed according to age groups (disease onset before or after 16 years) and genotype (high penetrance (HP) and low penetrance (LP) TNFRSF1A gene variants). Pediatric- and adult-onset were reported, respectively, in 44 and 36 patients; HP and LP variants were found, respectively, in 32 and 44 cases. A positive family history for recurrent fever was reported more frequently in the pediatric group than in the adult group (p<0.05…

0301 basic medicinemyalgiaMaleAbdominal painSettore MED/16 - REUMATOLOGIATNFRSF1AGene mutationGastroenterology0302 clinical medicinePathologyMedicineRB1-214PericarditisChildPrognosisPenetranceInflamacióFamilial Mediterranean FeverAIDA networkEstudi de casosReceptors Tumor Necrosis Factor Type IChild PreschoolAutoinflammationFemalemedicine.symptomResearch ArticleAdultmedicine.medical_specialtyArticle SubjectAdolescentGenotypetumor necrosis factorImmunologyContext (language use)Asymptomatic03 medical and health sciencesYoung AdultInternal medicineAnimalsHumansRetrospective Studies030203 arthritis & rheumatologyInflammationbusiness.industrytumor necrosis factor TRAPS AIDA networkTumor Necrosis Factor-alphaInfantTRAPSCell BiologyMyalgiaBiological productmedicine.disease030104 developmental biologyMutationCase studiesbusinessKidney diseaseMediators of Inflammation
researchProduct

Development and implementation of the AIDA International Registry for patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Ad…

2022

ObjectiveAim of this paper is to illustrate the methodology, design, and development of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to patients with the Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome.MethodsThis is a physician-driven, non-population- and electronic-based registry proposed to gather real-world demographics, clinical, laboratory, instrumental and socioeconomic data from PFAPA patients. Data recruitment is realized through the on-line Research Electronic Data Capture (REDCap) tool. This registry is thought to collect standardized information for clinical research leading to solid real-life evidence. Th…

Registryrare disease.PFAPA syndrome; autoinflammatory diseases; international registry; personalized medicine; precision medicine; rare diseaseprecision medicinerare diseaseautoinflammatory diseases; international registry; personalized medicine; PFAPA syndrome; precision medicine; rare diseasepersonalized medicineautoinflammatory diseasesSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory diseasePediatrics Perinatology and Child HealthHuman medicineinternational registryPFAPA syndrome
researchProduct

Measurement of inclusive jet and dijet cross sections in proton-proton collisions at 7 TeV centre-of-mass energy with the ATLAS detector

2011

Jet cross sections have been measured for the first time in proton-proton collisions at a centre-of-mass energy of 7 TeV using the ATLAS detector. The measurement uses an integrated luminosity of 17 nb−1 recorded at the Large Hadron Collider. The anti-k t algorithm is used to identify jets, with two jet resolution parameters, R=0.4 and 0.6. The dominant uncertainty comes from the jet energy scale, which is determined to within 7% for central jets above 60 GeV transverse momentum. Inclusive single-jet differential cross sections are presented as functions of jet transverse momentum and rapidity. Dijet cross sections are presented as functions of dijet mass and the angular variable χ. The res…

:Mathematics and natural science: 400::Physics: 430 [VDP]Physics and Astronomy (miscellaneous)4-Jet Observables:Mathematics and natural science: 400::Physics: 430::Nuclear and elementary particle physics: 431 [VDP]01 natural sciencesHigh Energy Physics - Experimentlaw.inventionHigh Energy Physics - Experiment (hep-ex)law[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Angular-DistributionsMediciónQuantum chromodynamicsPhysicsJet (fluid)MultiplicitiesLarge Hadron ColliderLuminosity (scattering theory)Settore FIS/01 - Fisica SperimentaleHERAATLASINCLUSIVE JET CROSS SECTIONmedicine.anatomical_structurePhotoproductionPhysical SciencesComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFísica nuclearLHCParticle Physics - ExperimentjetsParticle physicsCiências Naturais::Ciências FísicasStrong-Coupling Alpha(S)Astrophysics::High Energy Astrophysical Phenomena:Ciências Físicas [Ciências Naturais]FOS: Physical sciencesddc:500.2530Nuclear physicsAtlas (anatomy)0103 physical sciencesmedicineFysikRapidityddc:530High Energy Physics010306 general physicsColliderEngineering (miscellaneous)Ciencias ExactasHeraCalorimeterATLAS detector010308 nuclear & particles physicsParton DistributionsFísicaATLAS detector; proton-proton collisionsExperimental High Energy PhysicsHigh Energy Physics::ExperimentResolutionCollider
researchProduct

Musculoskeletal manifestations in children with Behçet's syndrome: data from the AIDA Network Behçet's Syndrome Registry

2023

AbstractThis study aims to describe musculoskeletal manifestations (MSM) in children with Behçet’s syndrome (BS), their association with other disease manifestations, response to therapy, and long-term prognosis. Data were retrieved from the AIDA Network Behçet’s Syndrome Registry. Out of a total of 141 patients with juvenile BS, 37 had MSM at disease onset (26.2%). The median age at onset was 10.0 years (IQR 7.7). The median follow-up duration was 21.8 years (IQR 23.3). Recurrent oral (100%) and genital ulcers (67.6%) and pseudofolliculitis (56.8%) were the most common symptoms associated with MSM. At disease onset, 31 subjects had arthritis (83.8%), 33 arthralgia (89.2%), and 14 myalgia (…

Settore MED/16 - REUMATOLOGIABehçet's diseaseBehçet’s syndromeArthritisArthritis; Behçet’s syndrome; International registry; Pediatric rheumatology; Rare diseasesRare diseasesSettore MED/38 - Pediatria Generale E SpecialisticaArthritis Behçet’s syndrome International registry Pediatric rheumatology Rare diseasesInternational registryEmergency MedicineInternal MedicineAutoinflammationPediatric rheumatologyArthriti
researchProduct

Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases

2022

ObjectiveThis paper points out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients affected by Undifferentiated Systemic AutoInflammatory Diseases (USAIDs).MethodsThis is an electronic registry employed for real-world data collection about demographics, clinical, laboratory, instrumental and socioeconomic data of USAIDs patients. Data recruitment, based on the Research Electronic Data Capture (REDCap) tool, is designed to obtain standardized information for real-life research. The instrument is endowed with flexibility, and it could change over time according to the scientific acquisitions an…

RegistrySettore MED/16 - REUMATOLOGIAprecision medicinerare diseasesGeneral Medicinepersonalized medicineautoinflammatory diseasesInternational RegistrySettore MED/38 - Pediatria Generale E Specialisticaautoinflammatory diseaseAutoinflammationHuman medicineInternational Registry; autoinflammatory diseases; personalized medicine; precision medicine; rare diseasesautoinflammatory diseases; International Registry; personalized medicine; precision medicine; rare diseases
researchProduct

The ATLAS Inner Detector commissioning and calibration

2010

The ATLAS Inner Detector is a composite tracking system consisting of silicon pixels, silicon strips and straw tubes in a 2 T magnetic field. Its installation was completed in August 2008 and the detector took part in data-taking with single LHC beams and cosmic rays. The initial detector operation, hardware commissioning and insitu calibrations are described. Tracking performance has been measured with 7.6 million cosmic-ray events, collected using a tracking trigger and reconstructed with modular pattern-recognition and fitting software. The intrinsic hit efficiency and tracking trigger efficiencies are close to 100%. Lorentz angle measurements for both electrons and holes, specific energ…

Physics - Instrumentation and DetectorsPhysics and Astronomy (miscellaneous)Physics::Instrumentation and DetectorsAstronomyTracking (particle physics)Modules7. Clean energy01 natural sciencesATLAS; calibrationHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Heavy IonsDetectors and Experimental TechniquesDetectors de radiacióPhysicsLarge Hadron ColliderDetectorSettore FIS/01 - Fisica SperimentaleInstrumentation and Detectors (physics.ins-det)ATLASAstrophysics and CosmologyTransition radiation detectormedicine.anatomical_structureIonization EnergyComputingMethodologies_DOCUMENTANDTEXTPROCESSINGLHCElementary ParticlesQuantum Field TheoryParticle physicsFOS: Physical sciencesCosmic rayddc:500.2HadronsSilicon Pixel Sensors530OpticsQuantum Field TheoriesAtlas (anatomy)0103 physical sciencesCalibrationmedicineddc:530High Energy Physics[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]Measurement Science and InstrumentationOptoelectronics010306 general physicsString TheoryEngineering (miscellaneous)ReadoutNuclear PhysicsATLAS detectorbusiness.industry010308 nuclear & particles physicsFísicaSemiconductor TrackerTransition radiationExperimental High Energy Physicsbusiness
researchProduct

Commissioning of the ATLAS Muon Spectrometer with cosmic rays

2010

The ATLAS detector at the Large Hadron Collider has collected several hundred million cosmic ray events during 2008 and 2009. These data were used to commission the Muon Spectrometer and to study the performance of the trigger and tracking chambers, their alignment, the detector control system, the data acquisition and the analysis programs. We present the performance in the relevant parameters that determine the quality of the muon measurement. We discuss the single element efficiency, resolution and noise rates, the calibration method of the detector response and of the alignment system, the track reconstruction efficiency and the momentum measurement. The results show that the detector i…

SystemAstrofísicaDriftPhysics - Instrumentation and DetectorsMuon SpectrometerPhysics and Astronomy (miscellaneous)Physics::Instrumentation and DetectorsTracking (particle physics)01 natural sciences7. Clean energyHigh Energy Physics - ExperimentDrift TubeMDTHigh Energy Physics - Experiment (hep-ex)Data acquisitionATLAS muon spectrometer[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Detectors and Experimental TechniquesNuclear ExperimentPhysicsLarge Hadron Collidercosmic ray eventsDetectorSettore FIS/01 - Fisica SperimentaleBeamInstrumentation and Detectors (physics.ins-det)ATLASmedicine.anatomical_structureTrack ReconstructionPhysical SciencesFísica nuclearLHCmuon measurementFOS: Physical sciencesCosmic rayddc:500.2530Nuclear physicsAtlas (anatomy)0103 physical sciencesCalibrationmedicineFysikddc:530High Energy Physics[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]010306 general physicsEngineering (miscellaneous)Ciencias ExactasMuonChambersMuon TrackCosmologiaATLAS detector010308 nuclear & particles physicsFísicaTrack SegmentPhysics::Accelerator Physicsproton-proton collisionsHigh Energy Physics::Experiment
researchProduct

Readiness of the ATLAS liquid argon calorimeter for LHC collisions

2010

The ATLAS liquid argon calorimeter has been operating continuously since August 2006. At this time, only part of the calorimeter was readout, but since the beginning of 2008, all calorimeter cells have been connected to the ATLAS readout system in preparation for LHC collisions. This paper gives an overview of the liquid argon calorimeter performance measured in situ with random triggers, calibration data, cosmic muons, and LHC beam splash events. Results on the detector operation, timing perfor-mance, electronics noise, and gain stability are presented. High energy deposits from radiative cosmic muons and beam splash events allow to check the intrinsic constant term of the energy resolutio…

Physics - Instrumentation and DetectorsPhysics and Astronomy (miscellaneous)large hadron colliderPhysics::Instrumentation and DetectorsMonte Carlo method7. Clean energy01 natural sciences010305 fluids & plasmasHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)Radiative transfer[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Detectors and Experimental TechniquesDetectors de radiacióPhysicsLarge Hadron ColliderAcceleradors de partículesDetectorSettore FIS/01 - Fisica SperimentaleInstrumentation and Detectors (physics.ins-det)ATLASLHC Collisionsmedicine.anatomical_structurePhysical SciencesComputingMethodologies_DOCUMENTANDTEXTPROCESSINGLHCNoise (radio)chemistry.chemical_elementFOS: Physical sciencesComputer Science::Digital Libraries530Partícules (Física nuclear)Nuclear physicsAtlas (anatomy)0103 physical sciencesmedicineATLAS; liquid argon; calorimeter; LHC; collisionsFysikddc:530High Energy Physics[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]010306 general physicsEngineering (miscellaneous)Ciencias ExactasArgónArgonCalorimeter (particle physics)010308 nuclear & particles physicsFísicachemistryExperimental High Energy PhysicsHigh Energy Physics::Experimentelectromagnetic shower
researchProduct

Measurement of the top quark-pair production cross section with ATLAS in pp collisions at $\sqrt{s}=7$  TeV

2011

A measurement of the production cross-section for top quark pairs($\ttbar$) in $pp$ collisions at $\sqrt{s}=7 \TeV$ is presented using data recorded with the ATLAS detector at the Large Hadron Collider. Events are selected in two different topologies: single lepton (electron $e$ or muon $\mu$) with large missing transverse energy and at least four jets, and dilepton ($ee$, $\mu\mu$ or $e\mu$) with large missing transverse energy and at least two jets. In a data sample of 2.9 pb-1, 37 candidate events are observed in the single-lepton topology and 9 events in the dilepton topology. The corresponding expected backgrounds from non-$\ttbar$ Standard Model processes are estimated using data-driv…

QuarkTop quarkParticle physicsleptonsleptonPhysics and Astronomy (miscellaneous)Physics::Instrumentation and DetectorsAtlas detector:Ciências Físicas [Ciências Naturais]Hadronddc:500.2TOP QUARK01 natural sciences7. Clean energydileptonHigh Energy Physics - ExperimentquarksNuclear physicspp collisionNaturvetenskap0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]ddc:530High Energy PhysicsNuclear Experiment010306 general physicsEngineering (miscellaneous)Ciencias ExactasPhysicsScience & TechnologyLarge Hadron ColliderATLAS detectorATLAS detector; LHC; pp collisions; leptons; quarks010308 nuclear & particles physicsAtlas (topology)Settore FIS/01 - Fisica SperimentaleHigh Energy Physics::PhenomenologyFísicaATLASPair productionHadronic Collisionsproton-proton collisionsFísica nuclearHigh Energy Physics::ExperimentLHCNatural Sciencespp collisionsParticle Physics - ExperimentLeptonThe European Physical Journal C
researchProduct

Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry

2022

© 2022 Elsevier Inc.Background/objectives: Long-term efficacy and safety of tocilizumab (TCZ) in adult-onset Still's disease (AOSD) mostly derive from small case series. Herein we report a registry-based study investigating TCZ efficacy and safety in a cohort of patients with AOSD evaluated by clinical and serum inflammatory markers as well as drug retention rate analysis. Methods: This is an international multicentre study analyzing data from patients with AOSD regularly enrolled in the AIDA registry. TCZ efficacy was evaluated between baseline and last follow-up assessment in terms of changes in the Pouchot score and laboratory findings. Drug-retention rate was estimated by the Kaplan-Mei…

RegistrieAdultMaleSettore MED/16 - REUMATOLOGIAInterleukin-6Innovative biotechnologiesTocilizumabAdult-onset Still's diseaseAntibodies Monoclonal HumanizedPersonalized medicineAdult-onset Still's disease; Innovative biotechnologies; Interleukin-6; Personalized medicine; TocilizumabSettore MED/38 - Pediatria Generale E SpecialisticaAnesthesiology and Pain MedicineRheumatologyInnovative biotechnologieStill's diseaseHumansFemaleRegistriesImmunotherapyTocilizumab.Still's Disease Adult-OnsetHuman
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease.

2019

Introduction: Only a few studies have reported the long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). We herein describe Anakinra (ANA) effectiveness expressed in terms of drug retention rate (DRR) and evaluate predictive factors of drug survival in sJIA and ASOD patients. Objectives: Examine the overall DRR of ANA in sJIA and AOSD patients. Explore the influence of biologic line of treatment, and the concomitant use of disease modifying anti-rheumatic drugs (cDMARDs) on DRR in the whole sample and stratified according to the disease thereafter; find eventual predictive factors associated with events l…

Settore MED/38 - Pediatria Generale E SpecialisticaAnakinraSettore MED/16 - REUMATOLOGIAAnakinra Systemic Juvenile Idiopathic Arthritis Still’s disease
researchProduct

Impact of smoking habit on adult-onset Still’s disease prognosis, findings from a multicentre observational study

2021

The objective of this study is to describe the possible prognostic impact of smoking habit on adult-onset Still’s disease (AOSD) patients, by the assessment of clinical characteristics, life-threatening complications occurrence, and mortality in smokers than non-smokers. A multicentre retrospective study of prospectively followed-up AOSD patients included in Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort was conducted. Out of 185 AOSD assessed patients, 45 smokers were identified. These showed a higher frequency of pericarditis (35.5% vs 16.4%, p = 0.011), pleuritis (33.3% vs 14.3%, p = 0.008), and abdominal pain (17.7% vs 6.4%, p = 0.035). Furthermore, sm…

Adultmedicine.medical_specialtyAbdominal painAdult-onset; Macrophage activation syndrome; Mortality; Smoking; Still’s diseasePericarditisRheumatologyInternal medicineRisk of mortalityHumansMedicineMortalityRetrospective Studiesbusiness.industryStill’s diseaseSmokingRetrospective cohort studyGeneral MedicinePrognosismedicine.diseaseAdult-onsetRheumatologyMacrophage activation syndromeMacrophage activation syndromeCohortmedicine.symptombusinessStill's Disease Adult-OnsetSerositis
researchProduct

The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.

2015

Autoinflammatory disorders (AIDs) are a novel class of diseases elicited by mutations in genes regulating the homeostasis of innate immune complexes, named inflammasomes, which lead to uncontrolled oversecretion of the proinflammatory cytokine interleukin-1β. Protean inflammatory symptoms are variably associated with periodic fever, depicting multiple specific conditions. Childhood is usually the lifetime in which most hereditary AIDs start, though still a relevant number of patients may experience a delayed disease onset and receive a definite diagnosis during adulthood. As a major referral laboratory for patients with recurrent fevers, we have tested samples from 787 patients in the perio…

Adultmedicine.medical_specialtyReferralProinflammatory cytokineDiagnosis DifferentialRheumatologyAcquired immunodeficiency syndrome (AIDS)Internal medicinePeriodic feverMedicineHumansAge FactorChildGenetic disorderInnate immune systembusiness.industryHereditary Autoinflammatory DiseasesAge FactorsGeneral Medicinemedicine.diseaseAdulthoodInterleukin-1βRheumatologyImmunity InnateHereditary Autoinflammatory DiseasePeriodic feverSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyRecurrent feverImmunologyAutoinflammationbusinessAutoinflammatory DisordersHuman
researchProduct